UCB's Global Corporate Website


Learn More: Pregnancy and Lactation Studies


Completed Studies

About the CRIB Study

CRIB was a pharmacokinetic study assessing the potential level of placental transfer of certolizumab pegol (CZP) from pregnant women to their infants. The study followed sixteen women (= 30 weeks gestation) who were already receiving CZP at approved doses.

Click here to access the full study publication

About the CRADLE Study

The primary objectives of the CRADLE pharmacokinetic study were to determine the concentration of certolizumab pegol (CZP) in human breast milk and the average daily infant dose, an estimation of the daily dose of maternal CZP ingested by the breastfeeding infant.

Click here to access the full study publication


Ongoing Studies

About the CHERISH Study

The purpose of the study is to assess systemic certolizumab pegol (CZP) exposure, the formation of anti-CZP antibodies and safety of CZP across the course of pregnancy in study participants with chronic inflammatory diseases.

Click here to access a more detailed description of the study and eligibility criteria